Stay updated with breaking news from Trepl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group Inc. shares dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet...
By Dean Seal A clinical trial of Replimune Group's RP1 as a treatment for cutaneous squamous cell carcinoma failed to meet its primary endpoints. The...
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have received an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in […]
Wedbush reissued their outperform rating on shares of Replimune Group (NASDAQ:REPL – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has a $52.00 price objective on the stock. Wedbush also issued estimates for Replimune Group’s Q3 2024 earnings at ($0.90) EPS, FY2024 earnings at ($3.57) EPS, FY2025 earnings […]
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as $13.34 and last traded at $13.34, with a volume of 529686 shares traded. The stock had previously closed at $14.29. Analyst Ratings Changes Separately, HC Wainwright reduced their price objective on […]